Zymeworks Presents Phase 1 Data for ZW191 at ESMO Congress
By United One News · AI-generated summary of 2 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
Zymeworks presented new clinical data for its antibody-drug conjugate ZW191 at the European Society for Medical Oncology Congress in Madrid on October 24, 2026.
- Zymeworks showcased new clinical data from the randomized dose-optimization portion of an ongoing Phase 1 study.
- The evaluated therapy is ZW191, a folate receptor alpha-targeting antibody-drug conjugate.
- The presentation took place during the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
Covered by 3 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Timeline
First to report: Globenewswire_fr (); 3 articles from 2 outlets so far.
Who is covering this story
- Center (2): Globenewswire_fr, PR Newswire Asia
Sources
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 — Globenewswire_fr (center, AI-estimated) ·
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 — Globenewswire_fr (center, AI-estimated) ·
- 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC — PR Newswire Asia (center, AI-estimated) ·